Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10036449HBVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS10050122HBVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS30085065HIVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20007380HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20007381HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20010779HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20035928HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20057329HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20021555HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TVIS20056904HPVENSG00000196639.7protein_codingHRH1NoNo3269P35367
TCGA Plot Options
Drug Information
GeneHRH1
DrugBank IDDB09185
Drug NameViloxazine
Target IDBE0000442
UniProt IDP35367
Regulation Typeantagonist
PubMed IDs34003459; 32943948
CitationsFindling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH: Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18.@@Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V: New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. doi: 10.2147/JEP.S256586. eCollection 2020.
GroupsApproved; Investigational; Withdrawn
Direct ClassificationPhenol ethers
SMILESCCOC1=CC=CC=C1OCC1CNCCO1
Pathways
PharmGKB
ChEMBLCHEMBL306700